Interpretation of Serological Complement Biomarkers in Disease

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2018 Nov 9

PMID 30405598

Citations 50

Authors

Kristina N Ekdahl

Barbro Persson

Camilla Mohlin

Kerstin Sandholm

Lillemor Skattum

Bo Nilsson

Affiliations

Soon will be listed here.

Abstract

Complement system aberrations have been identified as pathophysiological mechanisms in a number of diseases and pathological conditions either directly or indirectly. Examples of such conditions include infections, inflammation, autoimmune disease, as well as allogeneic and xenogenic transplantation. Both prospective and retrospective studies have demonstrated significant complement-related differences between patient groups and controls. However, due to the low degree of specificity and sensitivity of some of the assays used, it is not always possible to make predictions regarding the complement status of individual patients. Today, there are three main indications for determination of a patient's complement status: (1) complement deficiencies (acquired or inherited); (2) disorders with aberrant complement activation; and (3) C1 inhibitor deficiencies (acquired or inherited). An additional indication is to monitor patients on complement-regulating drugs, an indication which may be expected to increase in the near future since there is now a number of such drugs either under development, already in clinical trials or in clinical use. Available techniques to study complement include quantification of: (1) individual components; (2) activation products, (3) function, and (4) autoantibodies to complement proteins. In this review, we summarize the appropriate indications, techniques, and interpretations of basic serological complement analyses, exemplified by a number of clinical disorders.

Citing Articles

Complement activation and vascular complications after pediatric allogeneic hematopoietic stem cell transplantation.

Leimi L, Vettenranta K, Meri S Sci Rep. 2025; 15(1):7073.

PMID: 40016347 PMC: 11868490. DOI: 10.1038/s41598-025-91455-5.

C3 Glomerulopathy: A Current Perspective in an Evolving Landscape.

Magliulo E, Ravipati P Glomerular Dis. 2024; 4(1):200-210.

PMID: 39618492 PMC: 11606624. DOI: 10.1159/000542354.

Extracellular traps in peripheral blood mononuclear cell fraction in childhood-onset systemic lupus erythematosus.

Saisorn W, Santiworakul C, Phuengmaung P, Siripen N, Rianthavorn P, Leelahavanichkul A Sci Rep. 2024; 14(1):23177.

PMID: 39369134 PMC: 11455886. DOI: 10.1038/s41598-024-74705-w.

A Multiplexed Quantitative Proteomics Approach to the Human Plasma Protein Signature.

Nunez E, Gomez-Serrano M, Calvo E, Bonzon-Kulichenko E, Trevisan-Herraz M, Rodriguez J Biomedicines. 2024; 12(9).

PMID: 39335631 PMC: 11428418. DOI: 10.3390/biomedicines12092118.

Tuomivaara S, Fisher S, Hall S, Goin D, Mattis A, Den Besten P Environ Health. 2024; 23(1):66.

PMID: 39044276 PMC: 11267808. DOI: 10.1186/s12940-024-01102-1.

References

Howard Jr J . Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2017; 1412(1):113-128. DOI: 10.1111/nyas.13522. View

Nilsson U, Nilsson B . Simplified assays of hemolytic activity of the classical and alternative complement pathways. J Immunol Methods. 1984; 72(1):49-59. DOI: 10.1016/0022-1759(84)90432-0. View

Riedl M, Fakhouri F, le Quintrec M, Noone D, Jungraithmayr T, Fremeaux-Bacchi V . Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost. 2014; 40(4):444-64. DOI: 10.1055/s-0034-1376153. View

Rostoker G, Pawlotsky J, Bastie A, Weil B, Dhumeaux D . Type I membranoproliferative glomerulonephritis and HCV infection. Nephrol Dial Transplant. 1996; 11 Suppl 4:22-4. DOI: 10.1093/ndt/11.supp4.22. View

Jonsson G, Truedsson L, Sturfelt G, Oxelius V, Braconier J, Sjoholm A . Hereditary C2 deficiency in Sweden: frequent occurrence of invasive infection, atherosclerosis, and rheumatic disease. Medicine (Baltimore). 2005; 84(1):23-34. DOI: 10.1097/01.md.0000152371.22747.1e. View

Prohaszka Z, Nilsson B, Frazer-Abel A, Kirschfink M . Complement analysis 2016: Clinical indications, laboratory diagnostics and quality control. Immunobiology. 2016; 221(11):1247-58. DOI: 10.1016/j.imbio.2016.06.008. View

Mastellos D, Yancopoulou D, Kokkinos P, Huber-Lang M, Hajishengallis G, Biglarnia A . Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest. 2015; 45(4):423-40. PMC: 4380746. DOI: 10.1111/eci.12419. View

Skattum L, Martensson U, Sjoholm A . Hypocomplementaemia caused by C3 nephritic factors (C3 NeF): clinical findings and the coincidence of C3 NeF type II with anti-C1q autoantibodies. J Intern Med. 1998; 242(6):455-64. DOI: 10.1111/j.1365-2796.1997.tb00018.x. View

PETERS D, Martin A, Weinstein A, Cameron J, BARRATT T, Ogg C . Complement studies in membrano-proliferative glomerulonephritis. Clin Exp Immunol. 1972; 11(3):311-20. PMC: 1553661. View

10.

Daha M, Fearon D, Austen K . C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol. 1976; 116(1):1-7. View

11.

Mayer M . On the destruction of erythrocytes and other cells by antibody and complement. Cancer Res. 1961; 21:1262-9. View

12.

Schneider H, Yonker R, Katz P, Longley S, Panush R . Rheumatoid vasculitis: experience with 13 patients and review of the literature. Semin Arthritis Rheum. 1985; 14(4):280-6. DOI: 10.1016/0049-0172(85)90047-2. View

13.

Halloran P, Chang J, Famulski K, Hidalgo L, Salazar I, Merino Lopez M . Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients. J Am Soc Nephrol. 2014; 26(7):1711-20. PMC: 4483591. DOI: 10.1681/ASN.2014060588. View

14.

Gupta B, Raghav S, Agrawal C, Chaturvedi V, Hari Das R, Das H . Anti-MBL autoantibodies in patients with rheumatoid arthritis: prevalence and clinical significance. J Autoimmun. 2006; 27(2):125-33. DOI: 10.1016/j.jaut.2006.07.002. View

15.

Kavanagh D, Pappworth I, Anderson H, Hayes C, Moore I, Hunze E . Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?. Clin J Am Soc Nephrol. 2012; 7(3):417-26. PMC: 3302670. DOI: 10.2215/CJN.05750611. View

16.

Bygum A, Vestergaard H . Acquired angioedema--occurrence, clinical features and associated disorders in a Danish nationwide patient cohort. Int Arch Allergy Immunol. 2013; 162(2):149-55. DOI: 10.1159/000351452. View

17.

Durey M, Sinha A, Togarsimalemath S, Bagga A . Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol. 2016; 12(9):563-78. DOI: 10.1038/nrneph.2016.99. View

18.

Rother U . A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes. J Immunol Methods. 1982; 51(1):101-7. DOI: 10.1016/0022-1759(82)90386-6. View

19.

Nilsson B, Ekdahl K, Svarvare M, Bjelle A, Nilsson U . Purification and characterization of IgG immunoconglutinins from patients with systemic lupus erythematosus: implications for a regulatory function. Clin Exp Immunol. 1990; 82(2):262-7. PMC: 1535126. DOI: 10.1111/j.1365-2249.1990.tb05437.x. View

20.

Schick T, Steinhauer M, Aslanidis A, Altay L, Karlstetter M, Langmann T . Local complement activation in aqueous humor in patients with age-related macular degeneration. Eye (Lond). 2017; 31(5):810-813. PMC: 5437332. DOI: 10.1038/eye.2016.328. View